According to a recent report by Market.us, the Global Recombinant Human Serum Albumin Market size is expected to be worth around USD 223.5 Million by 2033 from USD 92.7 Million in 2023, growing at a ...

SNS Insider Unveils Strategic Insights into the U.S. Albumin Market’s Robust Growth—Valued at USD 4.35 Billion in 2023—As the Nation Continues to Lead Global Therapeutic Utilization Amid Advanced ...

Optibumin® 25 is the first recombinant 25% human serum albumin for closed-system biomanufacturing, offering consistency, sterility, and GMP compliance. For decades, plasma-derived HSA has ...

The positive results underscore rHA's potential as a viable alternative to plasma-derived human serum albumin, addressing a critical gap in global healthcare. The Phase 1 clinical study was a ...

It turns out that zinc ions tune the ability of human serum albumin (HSA), an abundant transport protein in the body, to better prevent α-synuclein from aggregating, a process directly linked to ...

Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute decompensation and ascites, the phase III randomized PRECIOSA trial showed.

A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a potential solution to China's supply shortage of this critical blood protein.

This is a classic symptom of kwashiorkor. Researchers suggest it may be caused by low amounts of human serum albumin, which is the most abundant protein in the liquid part of blood, or blood plasma.

An analysis conducted on UK Biobank data suggests a possible association between higher concentrations of serum albumin and a reduced risk of multiple sclerosis (MS). Albumin is the most abundant ...